Anthrax Vaccine Plan: VaxGen, Avecia To Produce 4,000 Test Doses In March
Executive Summary
VaxGen and Avecia each expect to produce 2,000 test doses of recombinant anthrax vaccine by the end of March under separate contracts with NIH's National Institute of Allergy & Infectious Diseases